Revenue Update on Aduro BioTech Inc(NASDAQ:ADRO)

Aduro BioTech Inc(NASDAQ:ADRO) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Earnings per share were $0.03.

Aduro BioTech Inc (ADRO) made into the market gainers list on Fridays trading session with the shares advancing 3.09% or 0.47 points. Due to strong positive momentum, the stock ended at $15.69, which is also near the day’s high of $15.7. The stock began the session at $15.25 and the volume stood at 2,87,876 shares. The 52-week high of the shares is $34.95 and the 52 week low is $7.26. The company has a current market capitalization of $1,016 M and it has 6,47,54,256 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 7, 2016, Thomas W. Dubensky (Chief Scientific Officer) sold 25,000 shares at $11.61 per share price.Also, On May 18, 2016, Dirk G. Brockstedt (Sr. VP of Research and Dev.) sold 905 shares at $8.20 per share price.On May 18, 2016, Gregory W Schafer (Chief Operating Officer) sold 905 shares at $8.20 per share price, according to the Form-4 filing with the securities and exchange commission.

Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live attenuated Listeria GVAX and cyclic dinucleotides (CDNs). Aduro’s lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207 ADU-623 ADU-214 ADU-741 CDN and STINGVAX. CRS-207 is based on Aduro’s Listeria platform. ADU-623 is Aduro’s first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *